Recent progress in development of dopamine receptor subtype-selective agents: Potential therapeutics for neurological and psychiatric disorders

被引：330

作者：

Zhang, Ao ^{[1
]}

Neumeyer, John L.

Baldessarini, Ross J.

机构：

[1] Chinese Acad Sci, Shanghai Inst Mat Med, Bioorgan & Med Chem Lab, Shanghai 201203, Peoples R China

[2] Harvard Univ, Sch Med, McLean Hosp, Med Chem Lab, Belmont, MA 02478 USA

[3] Harvard Univ, Sch Med, Dept Psychiat, Belmont, MA 02178 USA

[4] Harvard Univ, Sch Med, Program Neurosci, Belmont, MA 02178 USA

[5] McLean Hosp, Neuropharmacol Lab, Belmont, MA 02478 USA

来源：

CHEMICAL REVIEWS | 2007年 / 107卷 / 01期

关键词：

D O I：

10.1021/cr050263h

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

This review covers progress during 2000-2005 on the development of selective ligands targeting mainly to the five main dopamine (DA) receptors. Topics discussed include the pharmacology of dopamine receptor subtypes and the development of dopamine receptor subtype ligands. As for the latter, emphasis is on the receptor-selective ligands from D1 to D4. Generally, recent efforts in medicinal chemistry and neuropharmacology have yielded substantial numbers of compounds with activity and selectivity at each of these major DA receptors.

引用

页码：274 / 302

页数：29

共 50 条

[31] A Series of 18F-Labelled Pyridinylphenyl Amides as Subtype-Selective Radioligands for the Dopamine D3 Receptor
Hocke, Carsten
Maschauer, Simone
Huebner, Harald
Loeber, Stefan
Utz, Wolfgang
Kuwert, Torsten
Gmeiner, Peter
Prante, Olaf
CHEMMEDCHEM, 2010, 5 (06) : 941 - 948
[32] SUBTYPE-SELECTIVE CHOLECYSTOKININ RECEPTOR ANTAGONISTS BLOCK CHOLECYSTOKININ MODULATION OF DOPAMINE-MEDIATED BEHAVIORS IN THE RAT MESOLIMBIC PATHWAY
CRAWLEY, JN
JOURNAL OF NEUROSCIENCE, 1992, 12 (09): : 3380 - 3391
[33] Metabotropic glutamate receptor 3 as a potential therapeutic target for psychiatric and neurological disorders
Dogra, Shalini
Putnam, Jason
Conn, P. Jeffrey
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2022, 221
[34] Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders
Lees, GJ
DRUGS, 2000, 59 (01) : 33 - 78
[35] Pharmacology of AMPA/Kainate Receptor Ligands and Their Therapeutic Potential in Neurological and Psychiatric Disorders
Gordon J. Lees
Drugs, 2000, 59 : 33 - 78
[36] Development of a triazolobenzodiazepine-based PET probe for subtype-selective vasopressin 1A receptor imaging
Haider, Ahmed
Xiao, Zhiwei
Xia, Xiaotian
Chen, Jiahui
Van, Richard S.
Kuang, Shi
Zhao, Chunyu
Rong, Jian
Shao, Tuo
Ramesh, Perla
Aravind, Appu
Shao, Yihan
Ran, Chongzhao
Young, Larry J.
Liang, Steven H.
PHARMACOLOGICAL RESEARCH, 2021, 173
[37] Development of subtype-selective covalent ligands for the adenosine A2B receptor by tuning the reactive group
Beerkens, Bert L. H.
Wang, Xuesong
Avgeropoulou, Maria
Adistia, Lisa N.
van Veldhoven, Jacobus P. D.
Jespers, Willem
Liu, Rongfang
Heitman, Laura H.
IJzerman, Adriaan P.
van der Es, Daan
RSC MEDICINAL CHEMISTRY, 2022, 13 (07): : 850 - 856
[38] The development of selective antagonists for the human dopamine D-4 receptor as potential antipsychotic agents.
Kulagowski, JJ
Broughton, HB
Collins, I
Curtis, NR
Leeson, PD
Mawer, IM
Moyes, C
Ridgill, MP
Rowley, M
Baker, R
Emms, F
Freedman, SB
Marwood, R
Patel, S
Patel, S
Ragan, IC
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 211 : 113 - MEDI
[39] Identification of the dopamine autoreceptor in the guinea-pig retina as D2 receptor using novel subtype-selective antagonists
Weber, B
Schlicker, E
Sokoloff, P
Stark, H
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 133 (08) : 1243 - 1248
[40] Development of a novel class of subtype-selective nicotinic receptor antagonist:: Pyridine-N-substituted nicotine analogs
Dwoskin, LP
Wilkins, LH
Pauly, JR
Crooks, PA
MOLECULAR AND FUNCTIONAL DIVERSITY OF ION CHANNELS AND RECEPTORS, 1999, 868 : 617 - 619

← 1 2 3 4 5 →